The Company is a Korea-based company principally engaged in the research and development of new drug candidates. The Company is principally engaged in the technology transfer of new drug candidates prior to electroclinical clinical trials. The Company is principally engaged in the research and development of kinase inhibitor as well as others. In addition, the Company is also engaged in the building and supply of new drug development platforms based on artificial intelligence (AI) and research results. The Company was established on February 24, 2015. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on June 24, 2022.
Headquarters
18Th F, Songdogwahak-Ro, Yeonsu-Gu
Incheon; Incheon;
Contact Details: Purchase the Voronoi, Inc. (Incheon) report to view the information.
Website: http://voronoi.io
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service